Recent Developments and Progress in Chronic Myeloid Leukemia

In this segment, “Recent Developments and Progress in Chronic Myeloid Leukemia”, Jorge Cortes, MD, and Naveen Pemmaraju, MD, discuss recent progress and future directions in CML.

While tyrosine kinase inhibitors (TKIs) have transformed the natural history of CML, the emergence of resistance mechanisms contributes to failure in many patients and the continued need for novel agents. Treatment-free remission is now a goal of therapy in patients achieving a stable deep molecular response. In the future, improved access to TKI therapies and monitoring, biomarkers to optimize treatment selection, and better treatments for blast-phase CML will continue to improve patient outcomes.
Previous Article CAR-T vs. Bispecific Agents in the Treatment of Refractory Multiple Myeloma
Next Article Hot Topics in Chronic Lymphocytic Leukemia